Dynavax
Dynavax documents scientific employment alongside tuition reimbursement, confidential employee assistance and wellness support. These provide practical resources around a professional career, without being presented as proof that every scientist receives the same training or working arrangement.
- Employer
Overview
Dynavax documents scientific employment alongside tuition reimbursement, confidential employee assistance and wellness support. These provide practical resources around a professional career, without being presented as proof that every scientist receives the same training or working arrangement. Current ownership is explicit: Sanofi completed its acquisition in February 2026, with Dynavax continuing as a subsidiary.
The employee record also documents a staff retreat and community activity. Its provider profile was updated in May 2025, before the acquisition, so those findings are not described as a new post-integration survey. The benefits and careers material supply corroborating provision, while the assessment does not assume that all historical employee experiences transfer unchanged through an ownership transition.
Published profile: Top 30 Employers for Research & Innovation Careers 2027 — Dynavax.
At a glance
| Assessed U.S. headquarters / base | Emeryville, CA, US |
| Reported business origins | 1996 |
| Ownership update | Sanofi completed its acquisition on 10 February 2026; Dynavax became an indirect wholly owned subsidiary and its shares ceased Nasdaq trading. |
Contents
Principal activities and assessed operations
The category profiles below describe the named businesses, products, programmes or employee groups assessed in the linked rankings. Their scope follows each source.
Top 30 Employers for Research & Innovation Careers 2027 — Dynavax
Dynavax documents scientific employment alongside tuition reimbursement, confidential employee assistance and wellness support. These provide practical resources around a professional career, without being presented as proof that every scientist receives the same training or working arrangement. Current ownership is explicit: Sanofi completed its acquisition in February 2026, with Dynavax continuing as a subsidiary.
The employee record also documents a staff retreat and community activity. Its provider profile was updated in May 2025, before the acquisition, so those findings are not described as a new post-integration survey. The benefits and careers material supply corroborating provision, while the assessment does not assume that all historical employee experiences transfer unchanged through an ownership transition.
- Employing entity / assessed group: Dynavax (assessed U.S. employing group)
- Assessed workforce: US employees in documented scientific/research-development work and professional support; role and programme eligibility applies.
- Assessed U.S. headquarters / base: Emeryville, CA, US
- Reported business origins: 1996
Top 30 Pharmaceutical & Biotechnology Employers 2027 — Dynavax
Dynavax’s published benefits identify tuition reimbursement, confidential employee assistance and the Wellable wellness program. Its provider profile documents a staff retreat and community involvement. Sanofi completed its acquisition in February 2026, with Dynavax continuing as a subsidiary; the entry therefore identifies the current ownership rather than presenting it as an independent public company.
Great Place To Work’s U.S. profile, updated May 2025, reports 90% overall workplace endorsement. A published employee item records 96% agreement: “I am able to take time off from work when I think it's necessary.”
- Assessed workforce: U.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded. Legacy Dynavax survey predates February 2026 Sanofi acquisition; no Sanofi-wide or post-integration inference.
Activities covered by the rankings
Rankings and recognition — 2027
Recorded appearances in The Economy Rankings. Each entry concerns the assessed business, product, institution or workforce scope in the linked edition.
| Ranking | Edition / classification | Assessed scope |
|---|---|---|
| Employers for Research & Innovation Careers | 2027 · Tier III | US employees in documented scientific/research-development work and professional support; role and programme eligibility applies. |
| Pharmaceutical & Biotechnology Employers | 2027 · Tier III | U.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded. Legacy Dynavax survey predates February 2026 Sanofi acquisition; no Sanofi-wide or post-integration inference. |
Explore The Economy
The following articles provide wider sector context. They are not necessarily coverage of this specific entity or an endorsement by it.
Documented company information
February 2026 closing filing identifies principal executive offices at 2100 Powell Street, Suite 720, Emeryville, California. Source.
Sanofi completed acquisition February 10, 2026; Dynavax survived as an indirect wholly owned subsidiary and Nasdaq share trading ceased. Source.
Further reference
Corrections and Updates
Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.